Media headlines about Xencor (NASDAQ:XNCR) have trended somewhat positive on Sunday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Xencor earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.6856520921349 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research firms have recently weighed in on XNCR. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a report on Friday. Canaccord Genuity restated a “buy” rating and set a $36.00 price target on shares of Xencor in a research note on Tuesday, August 8th. Finally, Wedbush restated an “outperform” rating and set a $29.00 price target on shares of Xencor in a research note on Friday, June 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Xencor presently has an average rating of “Hold” and a consensus target price of $29.33.

Shares of Xencor (NASDAQ:XNCR) opened at 21.38 on Friday. Xencor has a 1-year low of $18.45 and a 1-year high of $29.38. The stock’s market cap is $1.00 billion. The stock’s 50 day moving average price is $22.61 and its 200 day moving average price is $23.05.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.10. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%. The business had revenue of $13.34 million during the quarter, compared to analyst estimates of $8.15 million. On average, equities research analysts anticipate that Xencor will post ($1.17) EPS for the current fiscal year.

In related news, major shareholder John S. Stafford III acquired 6,000 shares of Xencor stock in a transaction that occurred on Wednesday, June 28th. The stock was acquired at an average price of $19.94 per share, for a total transaction of $119,640.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder John S. Stafford III acquired 1,500 shares of Xencor stock in a transaction that occurred on Friday, June 16th. The shares were bought at an average price of $19.67 per share, with a total value of $29,505.00. The disclosure for this purchase can be found here. Insiders have sold a total of 34,766 shares of company stock valued at $739,408 in the last 90 days. Insiders own 4.03% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Xencor (XNCR) Share Price” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.